USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
EVAS THERAPEUTICS, LLC.
Address:
613 HUNTLEY HEIGHTS DRIVE
BALLWIN, MO
Phone:
N/A
URL:
N/A
EIN:
200017897
DUNS:
143727191
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $320,133.00 2
SBIR Phase II $1,365,616.00 1

Award List:

Novel Recombinant Anticoagulant Proteins

Award Year / Program / Phase:
2005 / SBIR / Phase I
Award Amount:
$152,652.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Phase I: Clot formation in the blood vessel (thrombosis) causes a broad range of serious clinical conditions, such as unstable angina, acute myocardial infarction, ischemic stroke, deep vein thrombosis, pulmonary embolism, disseminated intravascular coagulation,… More

Pharmacologic treatment of thromboembolism

Award Year / Program / Phase:
2009 / SBIR / Phase I
Award Amount:
$167,481.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Thromboembolic disorders are major causes of morbidity and mortality in the Western societies. Anticoagulants are pivotal agents in the prevention and treatment of arterial and venous thrombosis. The limitations of curr ently approved anticoagulant drugs have… More

Novel antithrombotic agents to prevent hemodialysis vascular access failure

Award Year / Program / Phase:
2012 / SBIR / Phase II
Award Amount:
$1,365,616.00
Agency:
HHS
Principal Investigator:
Tze-chein Wun – 636-527-4545
Abstract:
DESCRIPTION (provided by applicant): Currently, more than 60 % of end-stage renal diseases patients who require chronic hemodialysis are accessed through a native arteriovenous fistula (AVF) or synthetic graft (AVG). Unfortunately, primary failure rates were as high as 60 % at 6 months after AVF… More